LEADER 02132nam  2200601 a 450 
001 9910782897703321
005 20230721004855.0
010   $a0-309-17817-7
010   $a1-281-30023-3
010   $a9786611300234
010   $a0-309-11013-0
035   $a(CKB)1000000000714260
035   $a(SSID)ssj0000279034
035   $a(PQKBManifestationID)11210640
035   $a(PQKBTitleCode)TC0000279034
035   $a(PQKBWorkID)10259467
035   $a(PQKB)10930698
035   $a(MiAaPQ)EBC3378332
035   $a(Au-PeEL)EBL3378332
035   $a(CaPaEBR)ebr10225174
035   $a(CaONFJC)MIL130023
035   $a(OCoLC)923278378
035   $a(EXLCZ)991000000000714260
100   $a20080623d2008      uy             0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aEmerging safety science$b[electronic resource] $eworkshop summary /$fSally Robinson, Robert Pool, and Robert Giffin [rapporteurs] ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies
210   $aWashington, D.C. $cNational Academies Press$dc2008
215   $axvi, 134 p. $cill. (some col.)
300   $aWorkshop held April 23-24, 2007 in Silver Spring, MD.
311   $a0-309-11012-2 
320   $aIncludes bibliographical references (p. 115-116).
606   $aDrugs$zUnited States$xSafety measures$vCongresses
606   $aPharmaceutical biotechnology$zUnited States$vCongresses
606   $aDrugs$zUnited States$xDesign$vCongresses
615  0$aDrugs$xSafety measures
615  0$aPharmaceutical biotechnology
615  0$aDrugs$xDesign
676   $a615/.10289
701   $aRobinson$b Sally$0620917
701   $aPool$b Robert$0288454
701   $aGiffin$b Robert B$01510132
712 02$aInstitute of Medicine (U.S.).$bForum on Drug Discovery, Development, and Translation.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910782897703321
996   $aEmerging safety science$93786894
997   $aUNINA